- Home
- NAVI vs AUPH Comparison
NAVI vs AUPH Comparison
Compare NAVI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- AUPH
- Stock Information
- Founded
- NAVI 1973
- AUPH 1993
- Country
- NAVI United States
- AUPH Canada
- Employees
- NAVI N/A
- AUPH N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- AUPH Health Care
- Exchange
- NAVI Nasdaq
- AUPH Nasdaq
- Market Cap
- NAVI N/A
- AUPH 999.8M
- IPO Year
- NAVI N/A
- AUPH 1999
- Fundamental
- Price
- NAVI $11.85
- AUPH $8.18
- Analyst Decision
- NAVI Hold
- AUPH Strong Buy
- Analyst Count
- NAVI 8
- AUPH 2
- Target Price
- NAVI $13.25
- AUPH $11.50
- AVG Volume (30 Days)
- NAVI 724.7K
- AUPH 1.3M
- Earning Date
- NAVI 04-30-2025
- AUPH 05-05-2025
- Dividend Yield
- NAVI 5.40%
- AUPH N/A
- EPS Growth
- NAVI N/A
- AUPH N/A
- EPS
- NAVI 1.18
- AUPH 0.04
- Revenue
- NAVI $848,000,000.00
- AUPH $235,133,000.00
- Revenue This Year
- NAVI N/A
- AUPH $11.86
- Revenue Next Year
- NAVI $0.14
- AUPH $24.96
- P/E Ratio
- NAVI $10.09
- AUPH $204.50
- Revenue Growth
- NAVI N/A
- AUPH 33.97
- 52 Week Low
- NAVI $10.53
- AUPH $4.86
- 52 Week High
- NAVI $16.97
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- NAVI 47.14
- AUPH 56.33
- Support Level
- NAVI $10.92
- AUPH $7.92
- Resistance Level
- NAVI $12.07
- AUPH $8.32
- Average True Range (ATR)
- NAVI 0.59
- AUPH 0.34
- MACD
- NAVI 0.12
- AUPH 0.07
- Stochastic Oscillator
- NAVI 67.12
- AUPH 90.64
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.